Low-molecular-weight heparin prophylaxis using dalteparin extended out- of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients a double-blind, randomized comparison

Archives of Internal Medicine

Volumn 160, Issue 14, 2000, Pages 2208-2215

  Hull, Russell D ^a,g   Pineo, Graham F ^a   Francis, Charles ^b   Bergqvist, David ^c   Fellenius, Carin ^d   Soderberg, Karin ^d   Holmqvist, Anna ^d   Mant, Michael ^e   Dear, Richard ^f   Baylis, Barry ^g   Mah, Andrew ^a   Brant, Rollin ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d PFIZER INC   (United States)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^f Calgary General Hospital   (Canada)

^g FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HIP ARTHROPLASTY; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 18744433904     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.14.2208     Document Type: Article

References (73)

1. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-929.
2. Planes A, Vochelle N, Mazar F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement thrombosis and haemostasis. Thromb Haemost. 1988;60:407-410.
3. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip arthroplasty. JAMA. 1990;263:2313-2317.
4. Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med. 1991;151:1621-1624.
5. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand. 1991;62:33-38.
6. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am. 1991;73:484-493.
7. Levine MM, Hirsh J, Gent M. et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-551.
8. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303:543-548.
9. Planes A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anaesthesia. J Bone Joint Surg Br. 1991;73:418-423.
10. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J Bone Joint Surg Br. 1991;73:434-438.
11. Francis CW, Pellegrini VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-2915.
12. German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg. 1992;111:110-120.
13. Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost. 1992;67:28-32.
14. Hull RD, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370-1376.
15. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis. 1993;4(suppl 1):S33-S38.
16. Spiro TE, Johnson CJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med. 1994;121:81-89.
17. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after effective hip replacement. J Bone Joint Surg Am. 1994;76:3-14.
18. Hamulyak K, Lensing AWA, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low molecular weight heparin or oral anticoagulants for the prevention of deep vein thrombosis in elective hip and knee replacement? Thromb Haemost. 1995;74:1428-1431.
19. Francis CW, Pellegrini VD, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79:1365-1372.
20. Eriksson B, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
21. Samama CM, Clergue F, Barre J, Montefiore A, III P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Br J Anaesth. 1997;78:660-665.
22. Planes A, Samama M, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81:22-25.
23. Prevention of venous thromboembolism: International Consensus Statement. Int Angiol. 1997;16:3-38.
24. Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest. 1998;114(5 suppl):531S-560S.
25. Guyatt GH, Cook DJ, Sackett DL, Eckman M, Pauker S. Grades of recommendation for antithrombotic agents. Chest. 1998;114:441S-444S.
26. Bergqvist D, Benoni G, Bjorgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
27. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet. 1996;348:224-228.
28. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26-31.
29. Lassen MR, Borris LC, Andersen BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hiparthroplasty: The Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998; 89:281-287.
30. Dahl OE. Thromboprophylaxis in hip arthroplasty: new frontiers and future strategy. Acta Orthop Scand. 1998;69:339-342.
31. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995;80:299-306.
32. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Arch Intern Med. 1993;153:2221-2228.
33. Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am. 1997;79:319-325.
34. Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthroplasty Screening Study. Ann Intern Med. 1997;127:439-445.
35. Leclerc JR, Gent M, Hirsh J, Geerts WH. Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med. 1998;158:873-878.
36. Colwell CW Jr, Collis DK, Paulson R, et al. Enoxaparin versus warfarin: prevention venous thromboembolic disease following total hip arthroplasty with inpatient and three month post-discharge evaluation. J Bone Joint Surg. 1999;81: 932-940.
37. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525-1531.
38. Pellegrini VD Jr, Clement D, Lush-Ehmann C, Keller GS, Evarts CM. The John Charnley Award: natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop. 1996;333:27-40.
39. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989;95: 498-502.
40. Moser KM, Le Moine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439-444.
41. Hull RD, Raskob GE, Brant RF, et al, for the American-Canadian Thrombosis Study Group. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med. 2000;160:229-236.
42. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
43. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995;108:978-981.
44. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcome in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
45. Hull R, Pineo GF, Francis C, et al, for the North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000;160:2199-2207.
46. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134-144.
47. Vandermeulen EP, van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg. 1994;79:1165-1177.
48. Lumpkin MM. FDA Alert: FDA public health advisory. Anesthesiology. 1998;88: 27A-28A.
49. Comerota AJ, Katz ML, Grossi RJ, et al. The comparative value of noninvasive testing for diagnosis and surveillance of deep vein thrombosis. J Vasc Surg. 1988; 7:40-49.
50. Borris LC, Christiansen HM, Lassen MR, Olsen AD, Schott P. Comparison of real-time B-mode ultrasonography and bilateral ascending phlebography for detection of postoperative deep vein thrombosis following elective hip surgery: the Venous Thrombosis Group. Thromb Haemost. 1989;61:363-365.
51. Ginsberg JS, Caco CC, Brill-Edwards PA, et al. Venous thrombosis in patients who have undergone major hip or knee surgery: detection with compression US and impedance plethysmography. Radiology. 1991;181:651-654.
52. Davidson BL, Elliott CG, Lensing AWA, for the RD Heparin Arthroplasty Group. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med. 1992;117:735-738.
53. Wells PS, Lensing AW, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: a meta-analysis. Ann Intern Med. 1995;122:47-53.
54. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
55. Graafsma YP, Prins MH, Lensing WA, de Haan RJ, Huisman MV, Buller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost. 1997;78:1189-1192.
56. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2769.
57. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985;88:819-828.
58. Bookstein JJ, Silver TM. The angiographic differential diagnosis of acute pulmonary embolism. Radiology. 1974;110:25-33.
59. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford, England: Blackwell Scientific; 1987:93-407.
60. Mohr DN, Silverstein MD, Ilstrup DM, Heit JA, Morrey BF. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc. 1992;67:861-870.
61. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. J Bone Joint Surg Br. 1995;77:6-10.
62. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verifed pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg. 1991; 78:849-852.
63. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
64. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82: 203-205.
65. Rubenstein I, Murray D, Hoffstein V. Fatal pulmonary embolism in hospitalized patients: an autopsy study. Arch Intern Med. 1988;148:1425-1426.
66. Campling EA, Devlin HB, Hoite RW, Lunn JN. Report of the National Confidential Enquiry Into Perioperative Deaths: 1991/1992. London, England: National Confidential Enquiry Into Perioperative Deaths; 1993.
67. Campling EA, Devlin HB, Hoite RW, Lunn JN. Report of the National Confidential Enquiry Into Perioperative Deaths: 1992/1993. London, England: National Confidential Enquiry Into Perioperative Deaths; 1994.
68. Siragusa S, Serafini S, Beltrametti C, Barone M, Piovella F. The incidence of post-thrombotic syndrome after asymptomatic post-operative deep vein thrombosis: an inception cohort study [abstract]. Blood. 1998;92(suppl 1):47a.
69. Sackett DL, Richardson WS, Rosenberg W. Haynes RB, eds. Evidence-Based Medicine: How to Practice and Teach. New York, NY: Churchill Livingstone; 1997.
70. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
71. Murray DW, Britton AR, Bulstrode CJK. Tnromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br. 1996;78:863-870.
72. Detournay B, Planes A, Vochelle N, Fagnini F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics. 1998;13:81-89.
73. Marchetti M, Liberato NL, Ruperto N, Barosi G. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica. 1999; 84:726-729.